Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2017, Article ID 2095682, 6 pages
https://doi.org/10.1155/2017/2095682
Research Article

Study on the Clinical Safe and Effective Methods of Arsenic-Containing Compound-Qinghuang Powder in the Treatment of Myelodysplastic Syndrome

Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China

Correspondence should be addressed to Xiaomei Hu; moc.361@2_iemoaixuh

Received 3 May 2017; Revised 21 August 2017; Accepted 10 September 2017; Published 16 November 2017

Academic Editor: I-Min Liu

Copyright © 2017 Qianzhe Zhu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Tefferi and J. W. Vardiman, “Myelodysplastic syndromes,” The New England Journal of Medicine, vol. 361, no. 19, pp. 1826–1885, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. S. Xu, R. Ma, X.-M. Hu et al., “Clinical observation of the treatment of myelodysplastic syndrome mainly with Qinghuang Powder,” Chinese Journal of Integrative Medicine, vol. 17, no. 11, pp. 834–839, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Z. Sun, R. Ma, X. M. Hu et al., “Karyotype and DNA-Methylation Responses in Myelodysplastic Syndromes following Treatment with Traditional Chinese Formula Containing Arsenic,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 969476, 8 pages, 2012. View at Publisher · View at Google Scholar
  4. J. L. Ma, W. W. Qu, and X. M. Hu, “Correlationship of Clonal Selection of Treatmentwith Arsenic-containing Formula Qinghuang Powder in vivo Effects of Arsenic in Patients with Myelodysplastie Syndrome,” Chinese Journal of Information on Traditional Chinese Medicine, vol. 20, no. 6, pp. 8–10, 2013 (Dutch). View at Google Scholar
  5. Y. Wang, S. Fang, M. M. Song et al., “Safety of compound Qinghuang Powder in patients with myelodysplastic syndromes,” International Journal of Traditional Chinese Medicine, vol. 36, no. 12, pp. 1074–1077, 2014 (Chinese). View at Google Scholar
  6. Y. Wang, S. Fang, Z. Y. Deng et al., “Compound Qinghuang Powder in the treatment of patients with myelodysplastic syndromes,” International Journal of Traditional Chinese Medicine, vol. 37, no. 12, pp. 1091–1095, 2015 (Chinese). View at Google Scholar
  7. P. Vanlet, H. P. Horny, J. M. Bennet et al., “Definitions and standards in the diagnosis and treatment of myelodysplatic snydromes: consensus statements and report from a working conference,” Leukemia Research, vol. 31, pp. 727–736, 2007. View at Google Scholar
  8. S. H. Swerdlow, E. Campo, and N. L. Harris, Eds., WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC, Lyon, France, 2008.
  9. M. T. Voso, S. Fenu, R. Latagliata et al., “Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database,” journal of the American Society of Clinical Oncology, vol. 31, pp. 2671–2677, 2013. View at Google Scholar
  10. A. Tefferi, G. Barosi, R. A. Mesa et al., “International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT),” Blood, vol. 108, no. 5, pp. 1497–1503, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Liu, Y. Lu, Q. Wu, R. A. Goyer, and M. P. Waalkes, “Mineral arsenicals in traditional medicines: Orpiment, realgar, and arsenolite,” The Journal of Pharmacology and Experimental Therapeutics, vol. 326, no. 2, pp. 363–368, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. J. L. Ma, X. M. Hu et al., “The Research Development of the Pharmacokinetics in Treating Hematological Malignancy with the Chinese Arsenic Drugs,” International Journal of Traditional Chinese Medicine, vol. 34, no. 1, pp. 80–82, 2012 (Chinese). View at Google Scholar
  13. National Pharmacopoeia Editorial Board: Pharmacopoeia of china, Beijing: China Medical Science and Technology Press, 2015.
  14. X.-M. Hu, S. Tanaka, K. Onda et al., “Arsenic disulfide induced apoptosis and concurrently promoted erythroid differentiation in cytokine-dependent myelodysplastic syndrome-progressed leukemia cell line F-36p with complex karyotype including monosomy 7,” Chinese Journal of Integrative Medicine, vol. 20, no. 5, pp. 387–393, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. X.-M. Hu, B. Yuan, S. Tanaka et al., “Involvement of oxidative stress associated with glutathione depletion and p38 mitogen-activated protein kinase activation in arsenic disulfide-induced differentiation in HL-60 cells,” Leukemia & Lymphoma, vol. 55, no. 2, pp. 392–404, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. X. M. Hu, B. Yuan, S. Tanaka et al., “Arsenic disulfide-triggered apoptosis and erythroid differentiation in myelodysplastic syndrome and acute myeloid leukemia cell lines,” International Journal of Hematology, vol. 19, no. 6, pp. 352–360, 2014. View at Publisher · View at Google Scholar
  17. X. M. Hu, Y. Bo, M. M. Song et al., “Dose-dependent biphasic effects of arsenic disulfideon differentiation and apoptosis of HL-60 cells,” Current Topics in Pharmacology, vol. 17, no. 2, pp. 13–25, 2014. View at Google Scholar